NLS pharma-clinical-trial-box

The company has announced that the first patient was dosed in a trial evaluating bemcentinib in combination with the current standard of care, immune checkpoint inhibitor pembrolizumab and doublet chemotherapy, for the treatment of 1st line (1L) Non-Small Cell Lung Cancer (NSCLC) patients harboring STK11 mutations (STK11m). “Approximately 20% of non-squamous NSCLC patients harbor STK11m […]

Calliditas Therapeutics has announced results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients with primary IgA nephropathy. The trial met its primary endpoint with Nefecon demonstrating a highly statistically significant benefit over placebo in estimated glomerular filtration rate (eGFR) over the two-year […]

The company has announced the completion of the patient enrollment in the company’s phase 3 clinical study SPARKLE with the lead candidate drug Orviglance. “We are very pleased to have reached our enrollment target of 80 patients in the SPARKLE study within our recently updated timelines. This is a major milestone in the history of […]

The company has reported favorable safety and promising early signs of efficacy following an initial analysis of the phase Ib part of the clinical trial TRIFOUR. In collaboration with the Spanish Breast Cancer Group (GEICAM), this trial investigates the IL1RAP-binding antibody nadunolimab (CAN04) in combination with chemotherapy for treatment of triple-negative breast cancer (TNBC). In […]

Modus Therapeutics has announced positive top-line data from its lipopolysaccharide (LPS) provocation study, a key step in evaluating the potential of its lead asset, sevuparin, as a treatment for sepsis and other conditions with systemic inflammation. In this study, healthy volunteers received LPS to induce a transient systemic inflammation reaction together with one of three […]

The company has announced topline data from BGBC008, a phase 2 trial evaluating its lead compound bemcentinibin combination with MSD’s anti-PD-1 therapy pembrolizumab in 2L+ Non-Small Cell Lung Cancer (NSCLC) patients. “We are very encouraged by the topline data,” says Martin Olin, Chief Executive Officer of BerGenBio. “Treatment with bemcentinib in combination with pembrolizumab demonstrated […]